Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Opus Bio Inc.
DescriptionCell therapy consisting of CD34+ hematopoietic stem cells that are treated ex vivo with a Lentiviral delivery system expressing Factor VIII protein
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPreclinical
Standard IndicationHaemophilus
Indication DetailsTreat hemophilia A
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today